Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Baxter
Mallinckrodt
AstraZeneca
Boehringer Ingelheim
Dow

Last Updated: November 21, 2019

DrugPatentWatch Database Preview

HUMALOG PEN Drug Profile

See Plans and Pricing

« Back to Dashboard

When do Humalog Pen patents expire, and what generic alternatives are available?

Humalog Pen is a drug marketed by Lilly and is included in one NDA.

The generic ingredient in HUMALOG PEN is insulin lispro recombinant. There are forty drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the insulin lispro recombinant profile page.

Summary for HUMALOG PEN
US Patents:0
Applicants:1
NDAs:1
Suppliers / Packagers: 4
Clinical Trials: 130
DailyMed Link:HUMALOG PEN at DailyMed
Drug patent expirations by year for HUMALOG PEN
Recent Clinical Trials for HUMALOG PEN

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Sandra SobelPhase 4
Eli Lilly and CompanyPhase 2
Massachusetts General HospitalPhase 2/Phase 3

See all HUMALOG PEN clinical trials

Pharmacology for HUMALOG PEN
Ingredient-typeInsulin
Drug ClassInsulin Analog

US Patents and Regulatory Information for HUMALOG PEN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Lilly HUMALOG PEN insulin lispro recombinant INJECTABLE;INJECTION 020563-002 Aug 6, 1998 DISCN No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for HUMALOG PEN

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Lilly HUMALOG PEN insulin lispro recombinant INJECTABLE;INJECTION 020563-002 Aug 6, 1998   Start Trial   Start Trial
Lilly HUMALOG PEN insulin lispro recombinant INJECTABLE;INJECTION 020563-002 Aug 6, 1998   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Boehringer Ingelheim
Merck
Medtronic
Baxter
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.